Takeda Pharmaceutical Company Limited has returned to Amgen two molecules, AMG403 and AMG386, two investigational compounds, as part of the companies previously announced partnership.

In 2008, Takeda and Amgen formed a partnership under which Takeda is todevelop and commercialize for the Japanese market up to 13 molecules from Amgen's pipeline, one of which is included as an option. The collaboration included early to mid-stage clinical-stage candidates across a range of therapeutic areas, including oncology, inflammation, and pain. At the time of the announcement, the financial terms included an upfront cash payment to Amgen of $200 million. Takeda was also pay to Amgen up to $340 million in expected worldwide development costs for these molecules over the next several years, $362 million in success-based milestone payments, and double digit royalties on sales in Japan. Additionally, Takeda planned to acquire all the shares of Amgen's Japanese subsidiary, Amgen KK.

Takeda and Amgen will continue to collaborate on the development and commercialization of remaining molecules / products for the Japanese market, including Vectibix (panitumumab), a treatment for unresectable advanced or recurrent colorectal cancer.

Source: Takeda Pharmaceutical Company